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Enrofloxacin in
Poultry and Human
Health
To the Editor: Following logic
similar to that recently used by the US
Food and Drug Administration to
withdraw approval for enrofloxacin, a
recent letter estimated that fluoro-
quinolone use in poultry could com-
promise responses to antimicrobial
drugs in >24,000 persons per year in
the United States (1). However,
>99.9% of this estimated risk appears
to result from incorrect assumptions.
Potentially important corrections
include the following: 1) not attribut-
ing resistance from foreign travel and
human ciprofloxacin use to domestic
use of enrofloxacin in poultry (this
could reduce the estimated risk by
≈1/3) (2); 2) updating the estimated
fraction of human foodborne
Campylobacter infections caused by
poultry to reflect declines in microbial
loads on chicken carcasses since 1992
reduces the estimated risk by a factor
of perhaps 1/10 (3) (the cited 90%
estimate by Hurd et al. [1] was intend-
ed for use as part of a conservative
upper-bounding analysis, not as a
realistic point estimate); 3) replacing
an assumption that 10% of infected
persons would benefit from antimi-
crobial drug therapy with a more data-
based value of 0.6% (4) would
reduces the estimated risk by a factor
of 0.6/10 = 0.06; 4) replacing an
assumption that fluoroquinolones are
prescribed for all  affected patients
receiving antimicrobial drug treat-
ment (rather than, for example, eryth-
romycin) by a more realistic value of
fluoroquinolones being prescribed for
perhaps ≈50% of patients (2) reduces
the estimated risk by a factor of
≈50%; 5) replacing an assumption
that  all  such cases lead to compro-
mised responses with a more data-
driven estimate that perhaps ≈17% of
patients have compromised responses
would reduce the estimated risk by a
factor of 1/6 (5); and 6) recognizing
that reducing enrofloxacin use may
not decrease fluoroquinolone resist-
ance in all Campylobacter spp. from
food animals (effect not quantified)
(6). Together, such changes reduce the
estimated risk by a factor of at least
(1/3) × (1/10) × (0.6/10) × (1/2) ×
(1/6) = 0.00017, or by >99.9%. 
More notably, the calculation in
(1) also wrongly assumes that the
fraction of patients with fluoro-
quinolone-resistant infections times
the fraction of infections caused by
poultry gives the fraction of patients
with compromised response caused
by fluoroquinolone use in poultry. As
a simple counterexample, suppose
that 80% of all infections were caused
by poultry, with the rest caused by
something else (e.g., water), and that
all and only the 20% of infections
caused by the latter source are resist-
ant. Then the procedure in (1) would
estimate (80% of infections caused by
poultry) × (20% of infections resist-
ant) = 16% as the fraction of resistant
infections caused by poultry, even
though the correct answer is zero.
Thus, the basic logic of the calcula-
tion is flawed. 
Louis Anthony Cox, Jr*†
*Cox Associates, Denver, Colorado, USA;
and †University of Colorado Health
Sciences Center, Denver, Colorado, USA
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In response: Cox’s letter (1) con-
tains a number of false assumptions,
errors, misleading assertions, and
misquotations. Cox asserts that annu-
ally 1 person or fewer in the United
States will experience an adverse
effect because of fluoroquinolone use
in poultry. He reduces 10-fold my ref-
erenced risk for persons acquiring
Campylobacter infections from poul-
try (2). His unrealistically low esti-
mate is not given in his referenced
citation. His estimated risk is also
much lower than in the reference 2,
which Cox himself quotes, “Poultry is
the most common cause of sporadic
cases of campylobacteriosis in the
United States” (Economic Research
Service of the US Department of
Agriculture) (3). Cox knows that his
assertion (4) that poultry make little or
no contribution to human
Campylobacter infections has been
extensively examined and found to be
wrong. Indeed, an entire section in a
recent US Food and Drug
Administration (FDA) determination
was written about the unreliability of
Cox’s testimony and these assertions,
a finding made by both the FDAcom-
missioner and an administrative law
judge (5,6).
Cox also misquotes Busby et al.
(3) when he asserts that only 0.6% of
persons with Campylobacter infec-
tions benefit from antimicrobial
drugs. The Busby article states that
0.6% of persons with Campylobacter
infections need “hospitalization,” not
how many would benefit from antimi-
crobial drug therapy. Cox has thus
made a misleading attribution (some-
thing he has previously been found to
do [5]). 
Busby et al. (3) estimated that in
1993,  ≈1,500,000 persons in the
United States acquired Campylo-
bacter infections from food sources.
Even if the proportion who can bene-
fit from receiving antimicrobial drugs
is as low as 2%, this translates to
30,000 persons. If 20% of these infec-
tions were caused by fluoro-
quinolone-resistant  Campylobacter
spp., then 6,000 persons would poten-
tially have their therapy and outcome
compromised, rather than the 1 person
that Cox would have us believe. More
realistic is the figure of 24,000 per-
sons estimated previously to be at risk
of having an adverse outcome (or
≈285 persons for every 1 million
chickens treated with fluoro-
quinolones) (1). Cox’s assumptions
and calculations thus seem flawed and
unrealistic.
Peter Collignon*
*The Canberra Hospital, Woden, Australian
Capital Territory, Australia 
References
1.  Cox LA. Enrofloxacin in poultry and
human health [letter]. Emerg Infect Dis.
2006;12:872–3.
2. Collignon P. Fluoroquinolone use in food
animals [letter]. Emerg Infect Dis.
2005;11:1789–80.
3.  Busby JC, Roberts T, Jordan Lin C-T,
MacDonald JC. Bacterial food-borne dis-
ease: medical costs and productivity losses.
[cited 2006 Mar 8]. Agricultural Economics
Report No. (AER741). Washington: United
States Department of Agriculture; 1996.
Available from http://www.ers.usda.gov/
publications/aer741/
4. Phillips I, Casewell M, Cox T, DeGroot B,
Friis C, Jones RN, et al. Does the use of
antibiotics in food animals pose a risk to
human health? A critical review of pub-
lished data. J Antimicrob Chemother.
2004;53;28–52.
5. US Food and Drug Administration. Final
decision of the commissioner. Proposal to
withdraw the approval of the new animal
drug application for enrofloxacin for poul-
try [cited 2006 Mar 8]. Docket no. 2000N-
1571. p. 16–7; 108–19. Available from
http://www.fda.gov/oc/antimicrobial/baytri
l.pdf. 
6. US Food and Drug Administration. Initial
decision. Withdrawal of approval of the
new animal drug application for
enrofloxacin for poultry [cited 2006 Mar 8].
Docket no. 00N-1571. p. 13–5. Available
from http://www.fda.gov/ohrms/dockets/
dailys/04/mar04/031604/00n-1571-
idf0001-vol389.pdf
Address for correspondence: Peter Collignon,
Infectious Diseases Unit and Microbiology
Department, The Canberra Hospital, Australian
National University, PO Box 11, Woden, ACT
2607, Australia; email: peter.collignon@act.
gov.au
Biodefense Shield
and Avian Influenza 
To the Editor: In defending
against avian influenza virus H5N1,
the possibility of adopting treatments
being developed for biodefense
should not be overlooked. Biodefense
medicine primarily concerns respira-
tory infections because bioweapons in
their deadliest form disperse Bacillus
anthracis and  Yersinia pestis, the
causes of anthrax and plague, and
highly contagious viruses like small-
pox, Ebola, and Marburg as aerosols.
The National Institutes of Health and
Department of Defense have funded
developing novel biodefense medica-
tions designed to stimulate innate
mucosal immunity by using interfer-
ons (IFNs) and interferon inducers.